2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

9:00AM-11:00AM: Abstract Number: 207

Direct Medical Costs of Systemic Lupus Erythematosus in South Korea

Health Services Research Poster I

9:00AM-11:00AM: Abstract Number: 821

Discrepancies between Clinical- and Imaging-Based Assessments of Disease Activity in Takayasu’s Arteritis

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 347

Disease Burden at One Academic Rheumatology Routine Care Setting Is Similar in Osteoarthritis (OA) and Rheumatoid Arthritis (RA) at First Visit but Significantly Greater in OA at a 6-Month Follow-up Visit

Patient Outcomes, Preferences, and Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 459

Disease Course in Seronegative RA Patients Classified According to the 2010 ACR/EULAR Criteria

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 450

Disease Duration and Withdrawal of Biologic Agents Predict Radiological Progression in a Cohort of Rheumatoid Arthritis Patients in Latin America. a Real World Study

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 219

Disparities in Patients’ Expectations of Foot and Ankle Surgery

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 575

Distinct Clinical and Immunological Features of Anti-Centromere Antibody Positive Primary Sjögren’s Syndrome: A Single Center Cross-Sectional Cohort Study

Sjögren's Syndrome Poster I: Translational Research

9:00AM-11:00AM: Abstract Number: 679

Distinct Interferon Scores Are Separately Associated with Activity and Long Term Sequelae in SLE

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 707

Distinctive Features of Positive Anti-Cell Antibody Tests on HEp-2 Cells (HEp-2-ANA) in Patients with Non-Autoimmune Diseases

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 229

Divergent Measures of Lupus Disease Damage and Severity Among Asians in an Ethnically Diverse Cohort

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 294

DNA Area and Netosis Analysis (DANA): A High-Throughput Method to Quantify Neutrophil Extracellular Traps in Fluorescent Microscope Images

Innate Immunity and Rheumatic Disease Poster I

9:00AM-11:00AM: Abstract Number: 221

Do Immigrant Communities Play a Role in Total Knee Arthroplasty (TKA) Outcomes?

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 444

Do Rheumatoid Arthritis Clinical Disease Activity Index Based Treat-to-Target Treatment Decisions Always Correspond to Usual Care Treatment Decisions at Point of Care?

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 427

Do We Treat Men and Women Differently, and Is This a Good Thing?

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 697

Does Erythrocyte Sedimentation Rate Reflect and Discriminate Flare from Infection in Systemic Lupus Erythematosus? Correlation with Clinical and Laboratory Parameters of Disease Activity

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].